RTI Biologics, a provider of orthopedic and sterile biological implants, in response to inquiries regarding Medtronic’s acquisition of Osteotech, has reported that its relationship with Medtronic continues to be strong, with no changes near-term.
RTI chairman and CEO Brian Hutchison said that they have received confirmation from Medtronic that their relationship is business as usual and they remain supportive of current agreement, which runs through June 2014.
“Both companies have taken several steps over the years to continuously improve our relationship, and we have been assured that Medtronic will continue down that path with RTI. At this time we expect to continue to meet Medtronic’s spinal allograft needs with high-quality, BioCleanse-sterilized biologic implants,” Hutchison said.
RTI prepares human donated tissue and bovine tissue for transplantation through testing and screening, precision shaping and using proprietary, validated processes.
The allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.